[CAS NO. 1135695-98-5] Q-VD-Oph

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1135695-98-5]

Catelog

SLK-S7311

Brand

Selleck

CAS

1135695-98-5

DESCRIPTION [1135695-98-5]

Overview

MDL	MFCD08669741
Molecular Weight	513.49
Molecular Formula	C26H25F2N3O6
SMILES	O=C(O)C[C@H](NC([C@@H](NC(C1=NC2=CC=CC=C2C=C1)=O)C(C)C)=O)C(COC3=C(F)C=CC=C3F)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.9475 mL	9.7373 mL	19.4746 mL
5 mM	0.3895 mL	1.9475 mL	3.8949 mL
10 mM	0.1947 mL	0.9737 mL	1.9475 mL
50 mM	0.0389 mL	0.1947 mL	0.3895 mL

Description

Q-VD-Oph (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a potent pan- inhibitor with ranged from 25 to 400 nM for caspases 1,3,8, and 9. Q-VD-OPh can inhibits HIV infection.

Targets

Caspase-1 ^[1]	Caspase-3 ^[1]	Caspase-8 ^[1]	Caspase-9 ^[1]
25 nM-400 nM	25 nM-400 nM	25 nM-400 nM	25 nM-400 nM

In vitro

Q-VD-OPh （5-100 μM） potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro.

In vivo

Q-VD-OPh inhibits caspase-1 activity, IL-18 protein expression, and neutrophil infiltration during ischemic ARF in mice. In vivo, caspase inhibition by Q-VD-OPh provides protection from virus-induced myocardial injury, with a significant reduction in caspase-3 activity. In TgCRND8 mice, Q-VD-OPh inhibits caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage.

References

[1] Mischak R. ICN Bioconcepts. 2002, 8, 1–5.
[2] Caserta TM, et al. Apoptosis. 2003, 8(4), 345-352.
[3] Melnikov VY, et al. J Clin Invest. 2002, 110(8), 1083-1091.
[4] DeBiasi RL, et al. J Virol. 2004, 78(20), 11040-11050.
[5] Rohn TT, et al. Int J Clin Exp Med. 2009, 2(4), 300-308.